Activating mutations in Kras have been observed in mouse EMT[18, 35, 38], however in human breast cancer, the prevalence is somewhat low, as COSMIC[39] reports 80 instances that lack intrinsic subtype information (with the exception of MDA-MB-231 cells that are claudin low). This evidence concerns the gene KRAS and breast cancer.